Literature DB >> 29319139

The role of 99mTc-DTPA retrobulbar SPECT in staging and follow-up of Graves' orbitopathy.

László Galuska1, Sándor K Barna, József Varga, Ildikó Garai, Endre V Nagy.   

Abstract

The pathogenesis of Graves' orbitopathy (GO) is not completely understood. Coexistent hyperfunction of the thyroid gland is frequent; however, GO may also coexist with hypo- or euthyrodism. The course of GO is largely independent of thyroid function, although elevated serum TSH is known to negatively interfere with GO course. GO is severe in 10% of the cases; sight threatening complications may also develop. A successful therapy of GO requires the assesment of both the severity and activity of orbital inflammation. Based on relevant studies and our own experiences, the possible management choices are reviewed here. For this purpose, we compare the clinical value of imaging techniques for detecting the activity of the disease. During the last 15 years, we used 99mTc-DTPA retrobulbar SPECT routinely in more than 1400 patients to facilitate the right therapeutic decision. This diagnostic utility simplified management decisions compared to previously applied alternative techniques. We recommended the routine use of 99mTc-DTPA retrobulbar SPECT for the evaluation and follow-up of GO.

Entities:  

Keywords:  99mTc-DTPA; GO; hyperthyroidism

Mesh:

Substances:

Year:  2018        PMID: 29319139     DOI: 10.5603/NMR.a2018.0005

Source DB:  PubMed          Journal:  Nucl Med Rev Cent East Eur        ISSN: 1506-9680


  2 in total

1.  99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients.

Authors:  Dan Liu; Xueliang Xu; Sha Wang; Chengzhi Jiang; Xinhui Li; Jia Tan; Zhihong Deng
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

Review 2.  Multimodal Molecular Imaging: Current Status and Future Directions.

Authors:  Min Wu; Jian Shu
Journal:  Contrast Media Mol Imaging       Date:  2018-06-05       Impact factor: 3.161

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.